BRPI0506498A - composições compreendendo inibidor de hiv protease e inibidor de atividade de enzima de citocromo p450 - Google Patents

composições compreendendo inibidor de hiv protease e inibidor de atividade de enzima de citocromo p450

Info

Publication number
BRPI0506498A
BRPI0506498A BRPI0506498-8A BRPI0506498A BRPI0506498A BR PI0506498 A BRPI0506498 A BR PI0506498A BR PI0506498 A BRPI0506498 A BR PI0506498A BR PI0506498 A BRPI0506498 A BR PI0506498A
Authority
BR
Brazil
Prior art keywords
cytochrome
hiv protease
inhibitor
enzyme activity
compositions
Prior art date
Application number
BRPI0506498-8A
Other languages
English (en)
Inventor
Jonathan Quoc Tran
Evan Burr Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0506498A publication Critical patent/BRPI0506498A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"COMPOSIçõES COMPREENDENDO INIBIDOR DE HIV PROTEASE E INIBIDOR DE ATIVIDADE DE ENZIMA DE CITOCROMO P450". A presente invenção refere-se a métodos para aperfeiçoamento da farmacocinética de certos compostos úteis como inibidores da enzima HIV protease, por inibição da atividade de enzima de citocromo P450. A presente invenção também se refere a composições compreendendo cedos compostos úteis como inibidores da enzima HIV protease e pelo menos um agente que inibe a atividade de enzima de citocromo P450.
BRPI0506498-8A 2004-01-30 2005-01-17 composições compreendendo inibidor de hiv protease e inibidor de atividade de enzima de citocromo p450 BRPI0506498A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54074604P 2004-01-30 2004-01-30
US61499704P 2004-10-01 2004-10-01
PCT/IB2005/000110 WO2005082364A1 (en) 2004-01-30 2005-01-17 Compositions comprising hiv protease inhibitor and cytochrome p450 enzyme activity inhibitor

Publications (1)

Publication Number Publication Date
BRPI0506498A true BRPI0506498A (pt) 2007-02-13

Family

ID=34915539

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506498-8A BRPI0506498A (pt) 2004-01-30 2005-01-17 composições compreendendo inibidor de hiv protease e inibidor de atividade de enzima de citocromo p450

Country Status (15)

Country Link
US (1) US20050171037A1 (pt)
EP (1) EP1713478A1 (pt)
JP (1) JP2007519706A (pt)
KR (1) KR20060127939A (pt)
AR (1) AR047584A1 (pt)
AU (1) AU2005216712A1 (pt)
BR (1) BRPI0506498A (pt)
CA (1) CA2555173A1 (pt)
CO (1) CO5700739A2 (pt)
IL (1) IL176675A0 (pt)
MX (1) MXPA06008598A (pt)
NO (1) NO20063826L (pt)
RU (1) RU2006127429A (pt)
TW (1) TW200530204A (pt)
WO (1) WO2005082364A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009279520A1 (en) * 2008-08-07 2010-02-11 Merck Sharp & Dohme Corp. Pharmaceutical formulations of an HCV protease inhibitor in a solid molecular dispersion
JP6421873B2 (ja) * 2014-07-18 2018-11-14 ジェイダブリュ ファーマセウティカル コーポレーション テノホビルジソプロキシルの新規塩

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
JP2637847B2 (ja) * 1992-12-29 1997-08-06 アボツト・ラボラトリーズ レトロウィルス蛋白分解酵素を阻害する化合物
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
GEP20043251B (en) * 1999-04-07 2004-06-25 Pfizer Prod Inc Use of CYP2D6 Inhibitors in Combination Therapies
MXPA03010054A (es) * 2001-05-01 2004-04-02 Abbott Lab Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
US7094909B2 (en) * 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US7169932B2 (en) * 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
HN2002000136A (es) * 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
WO2005026114A1 (en) * 2003-09-17 2005-03-24 Pfizer Inc. Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses

Also Published As

Publication number Publication date
TW200530204A (en) 2005-09-16
NO20063826L (no) 2006-10-24
JP2007519706A (ja) 2007-07-19
MXPA06008598A (es) 2006-08-28
WO2005082364A1 (en) 2005-09-09
IL176675A0 (en) 2006-10-31
CO5700739A2 (es) 2006-11-30
EP1713478A1 (en) 2006-10-25
RU2006127429A (ru) 2008-02-10
KR20060127939A (ko) 2006-12-13
AU2005216712A1 (en) 2005-09-09
US20050171037A1 (en) 2005-08-04
AR047584A1 (es) 2006-01-25
CA2555173A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
DE602006020875D1 (de) Oberflächenaktive peroxycarbonsäurezusammensetzungen
WO2022035911A3 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
SV2009003227A (es) Composiciones de inhibidores de chk 1 ref. x-17672
HN2010002119A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
NZ618331A (en) Stable formulations of a hyaluronan-degrading enzyme
ATE479687T1 (de) Kinaseinhibitoren
WO2008027932A3 (en) Cytochrome p450 oxidase inhibitors and uses thereof
TW200613289A (en) Prodrugs of hiv protease inhibitors
NO20064358L (no) Svovelforbindelser som inhibitorer for hepatitt C-virum-NS3-serinprotease
BRPI0615223A2 (pt) inibidores das serina proteases
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
PA8846901A1 (es) Inhibidores de cinasa akt y p70 s6.
BRPI0609424B8 (pt) composto inibidor da dipeptidil peptidase-iv e composição farmacêutica compreendendo dito composto como um agente ativo
MX2009005881A (es) Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
CO6400140A2 (es) Derivados de benzotiazol como agentes anticancer
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
DK1704859T3 (da) Kontrol af androgen receptor-afhængig genenkspression ved inhibering af amin-oxidase-aktiviteten af lysin-specifik demetylase (LSD1)
TNSN07222A1 (en) Nematicidal compositions
UY30543A1 (es) Formulacion de aerosol para la inhalacion de beta- agonistas
CR8889A (es) Derivados de n-(1h-indolil)- 1h-indol-2- carboxamidas, su preparacion y su aplicacion en terapeutica
WO2008048121A3 (en) Macrocyclic cysteine protease inhibitors and compositions thereof
WO2009051223A1 (ja) 白内障処置のための医薬組成物
MX2024002885A (es) Inhibidor de la proteasa 3clpro.
BRPI0506498A (pt) composições compreendendo inibidor de hiv protease e inibidor de atividade de enzima de citocromo p450
UA96768C2 (uk) Лікарський засіб від lct-отруєнь

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]